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1. Introduction 
The mammalian target of rapamycin (mTOR) has attracted growing attention during the past 
decade due to the increase realization of it’s extraordinarily significance in cellular life-
sustaining activity on the one hand, and because of its crucial role in a variety of diseases, 
(including cancer, hamartoma syndromes, cardiac hypertrophy, diabetes and obesity) on the 
other. mTOR is an atypical serine/threonine protein kinase, belonging to the 
phosphatidylinositol kinase-related kinase (PIKK) family. Cumulative evidence indicates that 
mTOR acts as a ‘master switch’ of cellular energy-intensive anabolic processes and energy-
producing catabolic activities. It coordinates the rate of cell growth, proliferation and survival 
in response to extracellular mitogen, energy, nutrient and stress signals [1, 2]. mTOR 
functions within two distinct multiprotein complexes, mTORC1 and mTORC2, responsible 
for the different physiological functions. Thus, mTORC1 is considered mostly involved in the 
regulation of the translation initiation machinery influencing cell growth, proliferation, and 
survival, while mTORC2 participates in actin cytoskeleton rearrangements and cell survival. 
mTORC1 and mTORC2 were initially identified in yeast on the basis of their differential 
sensitivity to the inhibitory effects of rapamycin, mTORC1 being originally considered as 
rapamycin-sensitive and mTORC2 as rapamycin-insensitive [3-5]. 
The history of TOR began in the early 1970s when a bacterial strain, Streptomyces 
hygroscopicus, was first isolated from Rapa Nui island during a discovery program for anti-
microbial agents. These bacteria secrete a potent anti-fungal macrolide that was named 
rapamycin after the location of its discovery [6-9]. Later rapamycin was proven to have anti-
proliferative and immunosuppressive properties. In the beginning of 1990s, two rapamycin 
target genes titled TOR1 (the target of rapamycin 1) and TOR2 were discovered through the 
yeast genetic screens for mutations that counteract the growth inhibitory properties of 
rapamycin [10, 11]. Further studies revealed that rapamycin forms the complex with its 
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intracellular receptor, FK506-binding protein 12 kDa (FKBP12), This complex binds a region 
in the C-terminus of TOR kinase named FRB (FKB12-rapamycin binding) domain, what 
leads to the inhibition of TOR functions [12-14].  
At present, it becomes clear that mTORC1 and mTORC2 activities are mediated through 
diverse signaling pathways depending on the type of extracellular signal. Thus, signaling 
from growth factors is mediated predominantly through PI3K-Akt-TSC1/2 pathway and 
upregulates mTORC1 to stimulate translation initiation, while energy or nutrient depletion 
and stresses suppress mTORC1 via LKB1–AMPK cascade to trigger off the process of 
autophagy. In contrast, mTORC2 is insensitive to nutrients or energy conditions. mTORC2 
phosphorylates Akt and some other protein kinases regulating actin cytoskeleton and cell 
survival in response to growth factors and hormones. The physiological functions of mTOR 
continue to expand. It should be stressed, that the signaling throughout the complicated 
mTOR network, including branched pathways and feedback loops, is regulated 
predominantly by phosphorylation and includes myriads of phosphorylation events. 
Moreover, the complexity of mTOR regulation is amplified by the crosstalk with other 
signaling pathways, such as MAP kinase- or TNFα-dependent cascades, which activity is 
also determined by vast number of phosphorylations. The complication of mTOR signaling 
additionally increases due to the hierarchical character of multiple site-specific 
phosphorylations of the main mTOR targets. Up to date there are no full clarity, concerning 
which kinase is responsible for each site phosphorylation as well as functional role and 
precise mechanisms of each phosphorylation event. The better understanding of underlying 
molecular mechanisms is now especially essential since inhibitors of mTOR signaling are 
widely used as drugs in the therapy of cancer and neurodegenerative diseases. 
2. mTOR kinase structural organization 
Although mTOR has limited sequence similarities in eukaryotes, it demonstrates a high level 
of conservation in its key cellular functions. mTOR, also known as FRAP (FKBP12-rapamycin-
associated protein), RAFT1 (rapamycin and FKBP12 target), RAPT 1 (rapamycin target 1), or 
SEP (sirolimus effector protein), is a large 289 kDa atypical serine/threonine (S/T) kinase [15-
18] and is considered a member of the phosphatidylinositol 3-kinase (PI3K)-kinase-related 
kinase (PIKK) superfamily since its C-terminus shares strong homology to the catalytic 
domain of PI3K [19, 20]. mTOR and yeast TOR proteins share > 65% identity in carboxy-
terminal catalytic domains and about 40% identity in overall sequence [21]. At the amino-acid 
level, human, mouse and rat TOR proteins share a 95% identity [22, 23]. The knockout of 
mTOR in mice is embryonic lethal, indicating its physiological importance [24, 25].  
Structurally, mTOR contains 2549 amino acids and the region of first 1200 N-terminal amino 
acids contains up to 20 tandem repeated HEAT (a protein-protein interaction structure of 
two tandem anti-parallel α-helices found in Huntingtin, Elongation factor 3 (EF3), PR65/A 
subunit of protein phosphatase 2A (PP2A), and TOR) motifs [26]. Tandem HEAT repeats are 
present in many proteins and may form an extended superhelical structure responsible for 
protein-protein interactions. HEAT repeats region is followed by a FAT (FRAP, ATM, and 
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TRRAP (PIKK family members)) domain and FRB (FKPB12-rapamycin binding domain), 
which serves as a docking site for the rapamycin -FKBP12 complex formation. Downstream 
lies a catalytic kinase domain and a FATC (FAT Carboxyterminal) domain, located at the C-
terminus of the protein (Figure 1A). The FAT and FATC domains are always found in 
combination, so it has been hypothesized that the interactions between FAT and FATC 
might contribute to the catalytic kinase activity of mTOR via unknown mechanisms [26, 27]. 
 
Figure 1. A. The domain structure of mTOR. mTOR contains tandem HEAT repeats, central FAT 
domain, FRB domain, a catalytic kinase domain and the FATC domain. Rapamycin associates with its 
intracellular receptor, FKBP12, and the resulting complex interacts with the FRB domain of mTOR. 
Binding of rapamycin–FKBP12 to the FRB domain disrupts the association of mTOR with the mTORC1 
specific component Raptor and thus uncouples mTORC1 from its substrates, thereby blocking mTORC1 
signaling. B. Composition of mTORC1 and mTORC2. mTORC1 consists of mTOR, Raptor, PRAS40, 
mLST8 and Deptor. mLST8 binds to the mTOR kinase domain in both complexes, where it seems to be 
crucial for their assembly. Deptor acts as an inhibitor of both complexes. Other protein partners differ 
between the two complexes. mTORC2 contains Rictor, mSIN1, and Protor1. C. Schematic of the TSC1 
and TSC2 proteins. The functional domains (including GAP) on TSC1 and TSC2 are represented 
schematically. T2BD/T1BD — TSC2 and TSC1 binding domains respectively. 
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Up to date quite a few phosphorylation sites in mTOR have been reported, namely T2446, 
S2448, S2481 and S1261 and this list will be probably appended. S2481 is considered to be a 
site of autophosphorylation [28]. S2481 is the only site the phosphorylation of which is well 
established for regulating mTOR intrinsic activity [29, 30]; the significance of other 
phosphorylation sites for mTOR activity are not entirely clear. Recently, S1261 has been 
reported as a novel mTOR phosphorylation site in mammalian cells and the first evidences 
of this phosphorylation in regulating mTORC1 autokinase activity has been provided [31]. 
Although phosphorylation at T2446/S2448 was shown to be PI3K/Akt-dependent, mTORC1 
downstream kinase S6K has been also reported to phosphorylate these two sites [32]. The 
significance of this potential feedback loop is unknown, as it is not yet clear whether and 
how these phosphorylations influence mTOR activity  
Binding of rapamycin–FKBP12 to the FRB domain of mTOR disrupts the association of 
mTOR with mTORC1-specific component Raptor and thus divide mTORC1 from its targets, 
blocking mTORC1 signaling. However, whether rapamycin directly inhibits mTOR’s 
intrinsic kinase activity is still not entirely clear [3, 33, 34].  
The TOR complexes mTORC1 and mTORC2 
The mammalian mTORC1 and mTORC2 complexes perform non-overlapping functions 
within the cell. Thus, the best-known function of TORC1 signaling is the promotion of 
translation. Other mTORC1 functions include autophagy inhibition, promotion of the 
ribosome biogenesis and of the tRNA production. The main known mTORC2 activity is the 
phosphorylation and activation of AKT and of the related kinases — serum/glucocorticoid 
regulated kinase (SGK) and protein kinase C (PKC) [35]. It is also involved in cytoskeletal 
organization. Although both mTOR complexes exist predominantly in the cytoplasm, some 
data indicate that they could function in different compartments. Thus, upon nutrients and 
energy availability mTORC1 is recruited to lysosomes where it could be fully activated [36] 
and where it functions to suppress autophagy. Unlike mTORC1, mTORC2 according to the 
most recent data localizes predominantly in ER compartment where it could directly 
associate with ribosomes [37, 38]. Additionally, some data evidence that mTOR may actually 
be a cytoplasmic-nuclear shuttling protein. The nuclear shuttling could facilitate the 
phosphorylation of mTORC1 substrates under the mitogenic stimulation [39]. The unique 
compositions of mTORC1 and mTORC2 determine the selectivity of their binding partners. 
Up to date we know more about mTORC1 rather then mTORC2 probably due to the lack of 
available and wide-spreaded inhibitors of mTORC2 activity. 
TORC1 composition. Within the mammalian cells, TORC1 functions as a homodimer. Each 
monomer consists of mTOR, regulatory associated protein of mTOR (Raptor), proline-rich 
AKT substrate 40 kDa (PRAS40), DEP domain TOR-binding protein (Deptor) and 
mammalian lethal with Sec-13 protein 8 (mLST8, also known as GbL) [40, 41](Figure 1B). 
Raptor is a 150 kDa presumably non-enzymatic subunit of mTORC1 that is essential for the 
kinase mTORC1 activity in vitro and in vivo in response to insulin, nutrient and energy level. 
[42, 43]. It includes a highly conserved N-terminal region followed by 3 HEAT repeats and 7 
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WD40 (about 40 amino acids with conserved W and D forming four anti-parallel beta 
strands) repeats. The Raptor-mTOR interaction is very dynamic, and is thought to require 
the HEAT repeats of mTOR. It is established that Raptor is indispensable for mTOR to 
phosphorylate its main effectors p70S6 kinase (S6K1) and eukaryotic initiation factor 4E 
(eIF4E) binding protein 1 (4E-BP1), but whether Raptor positively or negatively regulates 
mTOR itself remains controversial [43]. Raptor is essential for mTORC1 complex formation 
and for the dimerization of TORC1 complexes as it provides direct interaction between TOR 
proteins from each monomer. Thus it can be considered to be a scaffolding protein that 
recruits substrates for mTOR thereby demonstrating a stimulating effect on mTOR activity 
[43]. Alternatively, other study has demonstrated that Raptor negatively regulates mTOR 
being tightly bound to the kinase [42]. There are also a hypothesis according to which at 
least two types of interaction exist between Raptor and mTOR depending on nutrients 
availability. One mTOR-Raptor complex that forms in the absence of nutrients is stable and 
leads to a repression of the mTOR catalytic activity. In contrast, the other complex that 
forms under nutrients-rich conditions is unstable, but it is important for in vivo mTOR 
function [42] (reviewed in [44]). Recent studies suggested that the phosphorylation status of 
Raptor could influence mTORC1 activity [45]. Phosphorylation on S722/792 is mediated by 
AMPK (AMP-activated protein kinase) and is required for the inhibition of mTORC1 
activity induced by energy stress [45], whereas phosphorylation of Raptor on S719/721/722 is 
mediated by the p90 ribosomal S6 kinases (RSKs) and contributes to the activation of 
mTORC1 by mitogen stimulation [45, 46]. Most recently, S863 in Raptor was identified as 
mTOR-mediated phosphorylation site responsible for the insulin-dependent activation of 
mTORC1 [47]. 
PRAS40, another subunit of mTORC1, has been defined as a direct negative regulator of 
mTORC1 function [48]. Initially, PRAS40 was identified as a novel substrate of Akt being 
directly phosphorylated at T246 near its C-terminus [49]. This phosphorylation releases 
inhibition of mTORC1 by PRAS40. Subsequent studies showed that PRAS40 associates with 
mTORC1 via Raptor and inhibits mTORC1 activity [48]. A putative TOR signaling motif, 
FVMDE, has been identified in PRAS40 and shown to be required for interaction with 
Raptor. Upon binding to Raptor, PRAS40 is phosphorylated on S183 by mTORC1 both in 
vivo and in vitro [50] Thus, PRAS40 has been implicated as a physiological substrate of 
mTORC1. Most recently, two novel sites in PRAS40 phosphorylated by mTORC1, S212 and 
S221, have been identified [51]. Rapamycin treatment reduced the phosphorylation of S183 
and S221 but not S212, indicating that besides mTORC1, other kinases may also regulate the 
phosphorylation of S212 in vivo [51].  
mLST8 has been identified after Raptor as a stable component of both mTOR complexes 
[52]. It consists almost entirely of seven “sticky” WD40 repeats, and has been initially shown 
to bind to the kinase domain of mTOR, leading to the hypothesis that mLST8 positively 
regulates mTOR kinase activity. It was proposed that mLST8 is essential for a nutrient- and 
rapamycin-sensitive interaction between Raptor and mTOR [52]. However, there is no 
substantial evidence to support this idea. It has been speculated, that mLST8 may 
participate in the amino acids mediated activation of TORC1 being insignificant for other 
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mechanisms of TORC1 activation [52]. Alternatively, recent studies demonstrated functional 
importance of mLST8 for the Rictor-mTOR interaction, evidencing that mLST8 is involved in 
mTORC2 rather than in mTORC1 activity. 
Deptor binds to mTOR at the FAT domain thus originally proposed to be a part of TORC1. 
Recently it has been identified as mTOR inhibitor that acts on both TORC1 and TORC2. The 
upstream regulators of Deptor still remain unknown [41]. 
mTORC2 composition and distinctions from mTORC1 
In 2004, mTORC2, containing mTOR, mLST8 and Rictor was identified [3, 4]. Since mTORC2 
complex was discovered later than mTORC1, its functions and regulatory mechanisms are 
less understood [3]. TORC2 and TORC1 contain common subunits, as is mTOR itself, 
mLST8 and Deptor, but instead of Raptor, mTORC2 includes two different subunits, Rictor 
(rapamycin-insensitive companion of mTOR) and mSin1 (mammalian stress-activated 
protein kinase (SAPK)-interacting protein 1) [3, 4, 53]. In addition, Protor (protein observed 
with Rictor) was also considered a component of mTORC2 (Figure 1B) [54, 55]. mTORC2 
was originally thought to be rapamycin-insensitive [3], however, further studies 
demonstrated that prolonged rapamycin treatment inhibits the assembly of mTORC2 as 
well as its activity towards Akt phosphorylation in certain cell lines [56].  
Rictor is the first identified TORC2 specific component [3, 4]. It represents a large protein 
with a predicted molecular weight of about 200 kDa. Although Rictor contains no apparent 
catalytic domain motifs [4], knockdown of Rictor results in the loss of actin polymerization 
and cell spreading, the main known mTORC2 functions [4]. It was shown that the Rictor-
mTOR complex does not affect the mTORC1 effectors S6K1 and 4E-BP1, but influence the 
activities of several proteins known as mTORC2 downstream targets, including 
phosphorylation of Akt, PKC and the focal adhesion proteins. 
mSin1 was recently identified as a novel component of mTORC2, which is important for 
both the complex assembly and function [57-59]. Sin1 is conserved among all eukaryotic 
species especially in the middle part of the sequence [60]. A Ras-binding domain and a C-
terminal PH domain have been identified recently [61]. The several experimental techniques 
showed the importance of Sin1 for mTORC2 function [62]. The interaction in vivo between 
Sin1 and Rictor is more stable than their interactions with mTOR probably due to the ability 
of Sin1 and Rictor to stabilize each other [59]. Thus knockdown of Sin1 decreases the 
interaction between mTOR and Rictor, suggesting that Sin1 is important for mTORC2 
assembly. Knockdown of Sin1 by RNAi in Drosophila and mammals crucially diminishes the 
Akt phosphorylation on S473 in vitro. The same effect was observed in Sin1−/− cells [58].  
Protor-1 and Protor-2 (also known as Proline rich protein 5 (PRR5) [54, 55] and PRR5-like 
(PRR5L) [63] are two newly identified mTORC2 interactors which have been identified as 
Rictor-binding or SIN1 binding proteins [54]. Up to date their functions remain unclear. It is 
currently accepted that they are dispensable for mTORC2 assembly as well as for its 
catalytic activity [54], although Protor stability is dependent on the production of other 
TORC2 components. It is possible that Rictor and Sin1 act as scaffold proteins for various 
complexes involving different kinases.  
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mLST8 and Deptor, as was mentioned above, are the components of both mTORC1 and 
mTORC2 complexes. 
3. Upstream regulation of mTOR signaling 
3.1. PI3K-AKT-TSC1/2 -“Classical” pathway of mTOR regulation 
Although this pathway is still considered to be the main way exerting multi-faceted control 
over mTORC1 activity which sense insulin and growth factors signals to regulate cell 
growth, at present it becomes clear that at least some of its components also function to 
mediate responses on other stimulus, such as energy, stress or nutrients which are provided 
by discrepant signaling pathways, described below. 
3.1.1. TSC1/TSC2 complex and Rheb protein 
The TSC1/TSC2 complex (tuberous sclerosis complex 1/2, TSC1/2) has been established as the 
major upstream inhibitory regulator of mTORC1 [64, 65]. This complex mediates signals from 
a large number of distinct signaling pathways to modulate mTORC1 activity predominantly 
via different phosphorylations of TSC2. Functioning as a molecular switch, TSC1/2 
suppresses mTOR’s activity to restrict cell growth during the stress, and releases its inhibition 
under the favorable conditions. The TSC1 and TSC2 genes were identified in 1997 and 1993 
respectively as the tumor-suppressor genes mutated in the tumor syndrome TSC 1(tuberous 
sclerosis complex) [66-68]. TSC is a multisystem disorder characterized by the development 
of numerous benign tumors (e.g. hamartomas) most commonly detected at the brain, 
kidneys, skin, heart and lungs. Genetic studies of TSC1 and TSC2 in humans, mice, Drosophila 
and yeast strongly suggest that these proteins act mainly as a complex. The 140 kDa TSC1 
(also known as hamartin) and 200 kDa TSC2 (also known as tuberin) proteins share no 
homology with each other and very little with other proteins (Figure 1C) TSC1 and TSC2 
associate through certain regions [69] giving a heterodimeric complex. The only known 
functional domain throughout these two proteins is a region of homology at the C-terminus 
of TSC2 to the GAP domain of small G-protein Rap1. Searches for a GTPase target regulated 
by the TSC2 GAP (GTPase-activating protein) domain revealed the small G-protein Rheb. 
Mammalian TSC2 was shown to accelerate the rate of GTP hydrolysis of Rheb, converting 
Rheb from the active GTP-bound to the inactive GDP-bound state [69, 70]. This evidences 
that Rheb is a direct target of TSC2 GAP activity, and TSC2 suppress Rheb function. While 
the GAP activity of TSC2 is necessary for the complex functionality, TSC1 is required to 
stabilize TSC2 and prevent its ubiquitin-mediated degradation [71, 72]. Under growth 
conditions, the TSC1/2 complex is inactive, thereby allowing Rheb-GTP to activate TORC1.  
Rheb is a member of the Ras superfamily that appears to be conserved in all eukaryotes and, 
despite the term ‘brain’ in its name, is in fact ubiquitously expressed in mammals. Whether 
a GEF protein (guanine-nucleotide exchange factor responsible for reverse process, i.e. 
change GDP-bound to GTP-bound state) for Rheb exists remains unknown. Several 
evidences demonstrate that Rheb positively regulates mTORC1. In particular, Rheb 
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overexpression stimulates S6K1 and 4EBP1 phosphorylation, which are indicators of 
mTORC1 activity. This effect can be reversed by mTOR inactivation or by rapamycin 
treatment, suggesting that Rheb primarily functions through TORC1 [59]. Although genetic 
and biochemical studies strongly suggest that GTP-bound Rheb potently activates mTORC1, 
the molecular mechanism is still unclear. Overexpressed Rheb was shown to bind to mTOR 
[73, 74]. Associations between endogenous Rheb and mTORC1 components have not been 
reported. In general, Ras-related small G-proteins bind to their downstream effectors mostly 
in the GTP-bound state. Surprisingly, Rheb has been found to bind stronger to mTOR in its 
GDP-bound or nucleotide-free states [74]. At the same time it has been shown that GTP-
bound Rheb rather than the GDP-bound stimulates mTOR kinase activity in vitro [74]. 
Although the mechanism by which Rheb-GTP activates mTORC1 has not been fully 
understood, it needs Rheb farnesylation and can be blocked by farnesyl transferase (FT) 
inhibitors. Recently, it was found that Rheb can directly interact with the FKBP12 
homologue FKBP38 (named also FKBP8), and this binding seems to be tighter with Rheb-
GTP [75]. That study suggests that Rheb-GTP binds to FKBP38 and triggers its release from 
mTORC1, stimulating mTORC1 activity (Figure 2). In support of this model, an 
independent study carried out that decreasing FKBP38 expression with antisense 
oligonucleotides blocked the growth inhibitory effects of TSC1–TSC2 overexpression [76]. 
Although more studies are needed, these findings suggest that FKBP38 might be a Rheb 
effector that regulates mTORC1 and, perhaps, unknown targets downstream of the 
TSC1/TSC2 complex and Rheb. 
3.1.2. The PI3K-AKT pathway joins TSC-mTORC1 regulation 
The responsiveness of mTORC1 signaling to growth factors and insulin is provided through 
activation of PI3K (phosphatidylinositol-3-kinase) and Akt kinase, but the precise 
mechanism is still not clear. Through PI3K signaling, Akt also termed PKB (serine/threonine 
protein kinase B) is activated by most growth factors to phosphorylate several downstream 
substrates [77]. 
PI3K is a heterodimeric protein containing an 85-kDa regulatory and a 110-kDa catalytic 
subunits (PIK3CA) [78, 79]. PI3K acts to phosphorylate a number of membrane phospholipids 
to form the lipid second messengers phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2 or 
PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3 or PIP3). In response to 
the upstream inputs, PI3K at the cell membrane is activated through the association of a 
ligand with its receptor, stimulating p85 to bind phosphorylated tyrosine residues of Src-
homology 2 (SH2) domain on the receptor. This association promotes the p110 catalytic 
subunit to transfer phosphate groups to the membrane phospholipids [78, 80]. Consequently 
these lipids, particularly PtdIns(3,4,5)P3, attract several kinases to the plasmalemma initiating 
the signaling cascade [78, 80]. PIP3 accumulation is antagonized by the well-known tumor 
suppressor, lipid phosphatase PTEN (phosphatase and tensin homolog deleted on 
chromosome 10), which converts PIP3 to PIP2. One important function of PIP3 is to recruit 
Akt as well as PDK1 (or PDPK1, 3-phosphoinositide-dependent protein kinase-1) [81] via 
their PH (pleckstrin homology) domains to the plasma membrane (Figure 2).  
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Akt, known as one of the major survival kinases, belongs to the AGC (PKA/PKG/PKC) 
protein kinase family and is involved in regulating a vast number of cellular processes, 
including transcription, proliferation, migration, growth, apoptosis and various metabolic 
processes [3, 82]. Being translocated to the plasma membrane, Akt undergoes partial 
activation through the phosphorylation of T308 residue within the activation loop by PDK1 
and following full activation through the additional phosphorylation at the hydrophobic 
motif site S473 by PDK2 [83]. After activation Akt quits the cell membrane to phosphorylate 
intracellular substrates. Particularly, Akt can translocate to the nucleus [80] where it 
influences the activity of transcriptional factors, including CREB (cAMP response element-
binding), E2F (eukaryotic transcription factor 2), NF-κB (nuclear factor kappa from B cells) 
through Iκ-K (inhibitor kappa B protein kinase), the forkhead transcription factors, in 
particular, FOXO1 and FOXO3 and murine double minute 2 (MDM2) which regulates p53 
activity [84, 85]. In addition, Akt is able to target some other molecules to influence cell 
survival including GSK-3β (glycogen-synthase kinase-3β), which regulates β-catenin protein 
stability, and BAD (the pro-apoptotic molecule Bcl-2-associated death promoter).  
Akt was the first kinase demonstrated to phosphorylate directly the TSC1/TSC2 complex in 
response to growth factors. Human TSC2 contains five predicted Akt sites (S939, S981, 
S1130, S1132 and T1462 on full-length human TSC2), all of which have been suggested to be 
subjects of phosphorylation by Akt (Figure 2). Importantly, the two sites were shown 
definitively to be targeted by Akt in mammalian cells, S939 and T1462 [86]. There is also 
evidence that either S1130 or S1132 is phosphorylated by Akt in vivo [87]. Finally, Akt can 
phosphorylate a peptide corresponding to the sequence surrounding S981 in vitro [88]. This 
residue has been identified as an in vivo phosphorylation site on TSC2 by tandem-MS 
analyses [89]. However, whether Akt phosphorylates S981 on full-length TSC2 within cells 
has not been conclusively demonstrated. 
The majority of studies postulated that activated AKT promotes TORC1 signaling by 
phosphorylating multiple sites on TSC2, thereby relieving inhibition of Rheb and activating 
TORC1 [86, 87, 90, 91]. The data obtained using phosphorylation-site mutants of TSC2 
demonstrate that Akt mediated phosphorylation of these sites inhibits the function of the 
TSC1–TSC2 complex in cells, however the molecular mechanism of this inhibition has been 
the subject of much debate (reviewed in [92]). One proposed mechanism involves disruption 
of the TSC1–TSC2 complex. However, this does not occur rapidly and, although it might 
contribute to the long-term effects of Akt on mTORC1 signaling, it cannot explain the 
immediate effects of Akt activation on mTORC1, which are blocked by Akt 
phosphorylation-site mutants of TSC2. Another proposed mechanism is based on the 
possibility that phosphorylation of TSC2 alters its subcellular localization, such that it can no 
longer act as a GAP for Rheb. One study supporting this mechanism found that growth 
factor stimulation led to increase of the TSC2 levels within the cytosolic fraction [93]. This 
effect was PI3K-dependent, stimulated by activated Akt and required both S939 and S981 on 
TSC2. In that study, both TSC1 and Rheb were found exclusively in the membrane fraction, 
and unlike TSC2, did not show an increase in the cytosolic fraction following growth-factor 
stimulation. From these findings it was concluded that Akt-mediated phosphorylation of  
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Figure 2. Growth factors and insulin regulation of mTORC signaling. mTORC1 activity is modulated 
by a number of positive (shown in red) and negative (shown in blue) regulators. Growth factors activate 
mTORC1 indirectly by suppressing the function of its negative regulator TSC1/TSC2 complex. TSC2 
contains a GAP domain that converts Rheb to its inactive, GDP-bound form. PI3K-AKT dependent 
phosphorylation inhibits the TSC1/2 complex, thereby relieving the TSC1/2-mediated repression of 
Rheb and allowing activation of TORC1. AKT also activates mTORC1 through negative 
phosphorylation of mTORC1 suppressor, PRAS40. FKBP38 appears to associate through the FRB 
domain of mTOR and trigger its release from mTORC1, thereby stimulating mTORC1 activation. 
TSC2 on S939 or S981 inhibits the TSC1/TSC2 complex by triggering release of TSC2 from 
TSC1 at an intracellular membrane also occupied by Rheb. This model points on the 
significant and rapid dissociation of TSC2 from TSC1 upon phosphorylation – something that 
has not been detected in the majority of studies to date. Recent studies have suggested that 
AKT mediated phosphorylation of TSC2 at S939 and S981 creates a binding site for a cytosolic 
anchor protein, 14-3-3 (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, theta polypeptide also known as YWHAQ, 1C5; HS1), a mechanism of regulation 
shared by several other Akt substrates [77]. Examining interactions between endogenous 14-
3-3 proteins and TSC2, another study found that S939 and T1462 were both required for 14-3-
3 binding to TSC2 downstream of PI3K signaling. It seems likely that 14-3-3 binding to TSC2 
(provided by some combination of phosphorylated S939, S981 and T1462) contributes to Akt-
mediated inhibition of TSC2. Binding of 14-3-3 to TSC2 can disrupt binding TSC2 to TSC1 
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and RHEB, which are associated with endomembranes [93]. However, in 14-3-3 pull-down 
experiments, both TSC1 and TSC2 were found to bind, and 14-3-3 did not affect the 
association between TSC1 and TSC2 [94, 95]. It also remains unclear whether TSC2 binding 
to14-3-3 hindered its GAP activity towards Rheb. Importantly, TSC2 is not an essential target 
of AKT during normal D. melanogaster development [96], suggesting the presence of possible 
additional targets for the AKT mediated regulation of mTORC1. 
Growth factors control mTORC1 independently of the TSC complex 
As was mentioned above, the PRAS40 binds Raptor and thereby inactivates mTORC1 [48, 
50, 57, 63]. In response to growth factors, Akt phosphorylates PRAS40 at T246. This 
phosphorylation leads to the dissociation of PRAS40 from mTORC1 resulting in a reduced 
ability of PRAS40 to inhibit TORC1 [48, 49, 57]. This was proposed to be mediated through 
14-3-3 binding of the phosphorylated PRAS40 [57]. Thus, bypassing TSC2, AKT 
phosphorylates PRAS40 and prevents its ability to suppress mTORC1 downstream effectors. 
The inhibition of PRAS40 by AKT is conserved; in Drosophila, the PRAS40 ortholog Lobe 
regulates TORC1 signaling [97]. PRAS40 is in turn a substrate of mTORC1, and mTORC1 
mediated phosphorylation of PRAS40 S183, [50, 63] has been proposed to negatively 
regulate mTORC1 signaling by competing with 4EBP1 and S6K for interaction with Raptor. 
PRAS40 is a direct inhibitor of mTORC1 and antagonizes the activation of the mTORC1 by 
RhebGTP. However, constitutive mTORC1 signaling in TSC2 null mouse embryonic 
fibroblasts, in which AKT signaling is largely inhibited owing to a negative feedback 
mechanism (see below), indicates that hyperactive Rheb can overcome PRAS40 mediated 
inhibition of mTORC1 [48]. Thus, the AKT pathway might stimulate mTORC1 through two 
interconnected mechanisms: by activating Rheb and/or by inhibiting PRAS40. 
3.2. mTORC1 activation by nutrients 
3.2.1. hVps34 PI-3-P kinase and Rag GTPases 
It has long been known that mTORC1 signaling is strongly inhibited in cells under the 
conditions of nutrient deficiency and that the re-addition of amino acids to starved cells can 
strongly stimulate mTORC1 activity [22, 98]. However, the mechanisms by which amino 
acids convey signals to mTORC1 remain largely unknown. Earlier studies demonstrated 
that silencing expression of TSC1/2 confers resistance to amino acid deprivation, indicating 
that TSC1/2 is involved in the regulation of mTOR function by amino acids [90]. It has been 
suggested that branched-chain amino acids, (such as leucine), activate mTORC1 by 
inhibiting TSC1/TSC2 or stimulating Rheb [62]. Consequently, inhibition of Rheb binding to 
mTOR is critical for the inhibitory effect of amino acid withdrawal on mTOR signaling [99]. 
However, other studies do not support this idea. Thus, in TSC-null cells (that lack either 
TSC1 or TSC2), the mTORC1 activity remains sensitive to amino acid deprivation, 
suggesting that other than TSC2, additional mechanisms may also be involved in the 
regulation of mTOR by amino acids [100]. Although Rheb is required for the amino acid 
stimulation of mTORC1, starving of amino acids has no effect on GTP loading [99-102]. 
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Therefore, while there is a requirement for GTP-bound Rheb to induct of mTORC1 by amino 
acids, amino acids probably do not affect Rheb activity – indicating that regulation of Rheb 
does not stimulate mTORC1 in response to amino acids. 
Recently, Ste20-related kinase MAP4K3 (mitogen activated protein kinase kinase kinase 
kinase 3) and the class III PI3K hVps34 (human vacuolar protein sorting 34) were proposed 
to be activated by amino acid and be involved in the transduction of signals from amino 
acids to mTORC1 [103-107]. While the mechanism by which MAP4K3 regulates mTORC1 
remains unknown, a mechanism for hVPS34 was recently proposed (Figure 3). According to 
this proposed mechanism, amino acids induce an extracellular calcium influx that activates 
calmodulin, which in turn binds and activates hVps34 [108]. hVps34 then generates PI-3-
phosphate (PI-3-P) instead of the PI-3,4,5-tris-phosphate generated by type I PI3Ks [109], 
that somehow activates mTORC1. The mechanism also involves the formation of a 
calmodulin-hVps34-mTORC1 supercomplex. However, the regulation of mTORC1 by 
hVps34 is thought to be specific to mammalian cells because in flies Vps34 does not regulate 
TORC1 [106]. This is unexpected because regulation of TORC1 by amino acids is known as 
very conserved. Furthermore, in certain mammalian cells, amino acids appear to inhibit 
rather than activate mVps34 [110]. However, additional studies are needed to clarify the 
roles of these proteins in TORC1 activation.  
Most recent studies identified Rag GTPases as activators of mTORC1 by sensing amino acid 
signals [111, 112]. Rag-mediated activation of TORC1 still requires Rheb, indicating that, 
during amino acid signaling, Rag complexes act upstream of Rheb. Rag family members 
(Rag A-D) belong to the Ras superfamily of GTPases. They are unique in their ability to 
dimerize through long C-terminal extensions. In the presence of amino acids, the dimeric 
Rag complex, which consists of a Rag A/B monomer and a Rag C/D monomer, binds Raptor 
and transport mTORC1 to lysosomes, the same intracellular compartment that contains 
Rheb [36, 111, 112]. Rag complexes are recruited to the lysosomal membrane by the trimeric 
Ragulator complex [36], which contains the proteins MP1 (MEK partner 1), p14 and p18. The 
GTP-loading of Rag A/B appears to be regulated by amino acids, and binding to TORC1 is 
observed most robustly under nutrient-rich conditions – when Rag A/B is in the GTP-bound 
state and Rag C/D is in the GDP-bound state [111, 112]. This model answers the question 
why mTORC1 activity cannot be stimulated by growth factors in the absence of amino acids. 
It also explains why Rag GTPases are not able to activate mTORC1 activity in vitro [111]. 
mTORC1 can be fully activated only under the conditions of amino acids availability, Rab-
dependent mTORC1 translocation to a Rheb-containing compartment, and Rheb activated 
by growth factors. However, there are many key aspects that remain to be discovered, such 
as how branched amino acids are detected by Rag GTPases and the identification of the Rag 
guanine exchange factor (GEF). 
3.2.2. PLD joins to amino acids dependent mTORC1 regulation  
Several data evidence that phosphatidic acid (PA) is essential for mTORC1 activation. The 
main mechanism for generating PA is the hydrolysis of phosphatidylcholine (PC) by 
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phospholipase D (PLD). In mammals PLD exists as two isoforms (PLD1 and PLD2) 
possessing different mechanisms of regulation and subcellular distribution [113]. PLD1 is 
predominantly localized under steady-state conditions at the Golgi complex, endosomes, 
lysosomes and secretory granules, and is regulated by two major signaling categories: 
growth factors/mitogens like EGF, PDGF, insulin and serum that implicate tyrosine kinases, 
and the small GTPase proteins from Arf, Ral and Rho families. PLD2 is largely associated 
with lipid rafts on the membrane surface. [113]. Both PLD1 and PLD2 have a strong 
requirement for PIP2 as a co-factor [113]. It has been shown that PLD1 activation stimulates 
PLD2 by increasing levels of PIP2 (product of PA metabolic modifications) [114]. This makes 
more clear the involvement of both PLD1 and PLD2 in the mTORC1 activation. The 
generation of PA by PLD can be suppressed by primary alcohols (such as 1-butanol) 
through the transphosphatidylation reaction whereby inert phosphatidyl-alcohol is 
generated instead of PA. This reaction has been widely used to examine PLD significance, 
and several studies have demonstrated that the activation of mTOR was sensitive to 
primary alcohols. Thus, 1-butanol was able to block almost completely the serum-stimulated 
phosphorylation of mTOR downstream targets, S6K1 and 4E-BP1 [115]. From these findings, 
it can be asserted that PLD production of PA plays an essential role in the mTOR signaling 
pathway). In skeletal muscle, PA stimulated S6 kinase phosphorylation, and 1-butanol 
suppressed S6 kinase phosphorylation [116]. Nutrient-dependent multimerization of mTOR 
was also suppressed by 1-butanol [117]. Therefore, primary alcohols-dependent suppression 
of PLD activity has been shown to suppress mTORC1 signaling in several cell models [114]. 
Several laboratories have shown that mTORC1 is activated in response to exogenously 
supplied PA. For example, exogenously provided PA stimulated the activation of S6 kinase 
and phosphorylation of 4E-BP1 in cancer HEK293 cells. The effect of PA was sensitive to 
rapamycin [115, 118] and was dependent on the presence of amino acids [115]. Coexpression 
of TSC1/2 was shown to inhibit PA-dependent stimulation of S6K. This indicates that PA-
induced S6K activity is mediated through TSC1/2-mTOR signaling. PA was also shown to 
activate mTOR in macrophages in an Akt-dependent manner [119].  
In addition, several studies have explored the influence of PLD1 and PLD2 expression on 
mTORC1 activation. Particularly it was reported that PLD2 overexpression increases S6K 
phosphorylation in MCF7 cells [120]. Overexpression of PLD1 also stimulated S6K 
phosphorylation in rat fibroblasts [121]. siRNA-mediated knockdown of PLD1 blocked S6K 
phosphorylation in B16 melanoma cells, and suppression of either PLD1 or mTOR led to 
melanoma cells differentiation [122]. 
At the same time, up to date the precise mechanism of PA-dependent stimulation of mTOR 
signaling remains unclear. One possibility is that PA binds to mTOR at the FRB domain, the 
region where the rapamycin-FKBP12 molecule binds mTOR as well. This binding was 
specific for PA as other phospholipids were unable to bind the FRB with such specificity. It 
was hypothesized that the competition between the rapamycin-FKBP12 complex and PA for 
the FRB site may be one of the regulating factors in mTOR activation [115]. According to the  
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Figure 3. Nutrients regulation of mTORC signaling. mTORC1 could be activated by amino acids 
through few proposed molecular mechanisms. In the response to amino acid sufficiency Rag complex is 
recruited to the lysosomal membrane by the trimeric Ragulator complex which consists of MP1, p14 and 
p18 thereby allowing Rheb to activate mTORC1. Amino acids also induce an extracellular calcium 
influx that activates calmodulin, which in turn binds and activates hVps34 that generates PI-3-P, what 
leads somehow to the mTORC1 activation. One model puts PLD downstream of hVps34 suggesting 
hVps34(PI-3-P)-PLD-mTORC1 pathway mediating response to amino acids. According to this model 
nutrient activation of PLD requires interaction with small G proteins RalA and Arf6. In addition, several 
studies evidence that PLD probably via generation of PA contributes to the mTORC1 activation in 
response to the nutrient stimulation. Particularly, PA could compete with rapamycin-FKBP12 complex 
for the mTOR FRB domain binding or reduce the pH around mTOR. PLD2 has also been reported to 
form a functional complex with mTOR and Raptor through a TOS (TOR signaling) motif. It has also 
been proposed that branched-chain amino acids could activate mTORC1 by inhibiting TSC1/TSC2 or 
stimulating Rheb. 
other hypothesis the pH locally around mTOR is reduced by PA-generated PLD, which 
eventually promotes its kinase activity, or allows for interaction with yet unknown 
promoter substrates [114]. It was shown that PLD1 is an effector of the small GTPase Rheb 
(see above) within the mTORC1 signaling pathway [123, 124] (Figure 3). It was also reported 
that PLD2 forms a functional complex with Raptor and mTOR via a TOS (TOR signaling) 
motif in PLD2, and this interaction was essential for mitogen stimulation of mTORC1 [125]. 
More recently, dominant negative mutants of both PLD1 and PLD2 were able to suppress 
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the activation of mTORC1 [126]. Therefore, besides PA ability to activate mTORC1, there are 
several data indicating requirement of PLD itself for the activation of mTORC1. Very recent 
study provided additional evidence that nutrient stimulation of mTORC1 is dependent on 
PLD activity which in turn is activated by small GTPases RalA and Arf6 [127]. According to 
this study, amino acids dependent activation of PLD is mediated trough generated by Vps34 
PI-3-phosphate [127], that could interact with PX domains of PLD1 and PLD2 which are 
known to be critical for PLD activity [128]. This activation also requires PLD interaction with 
both RalA and Arf6. Interestingly, these small GTPases have been earlier shown to be 
implicated in both responding to nutrients and the stimulation of PLD activity. RalA is 
constitutively associated with PLD1, but does not activate PLD1 by itself. RalA contributes 
to the activation of PLD1 by recruiting ARF6, which does activate PLD1 activity, into 
RalA/ARF6/PLD1 complex. While it is still not clear how the presence of nutrients activates 
RalA and ARF6, the data provided in this study indicate that PLD is a key target of RalA 
and ARF6 for the stimulation of mTORC1. In concordance with these findings data from our 
lab evidence that expression of constitutively active Arf6 stimulates PLD activity which 
leads to the mTORC1 dependent phosphorylation of downstream targets 4E-BP1, S6K1 
kinase and its effector ribosomal protein S6 (rpS6). We also show that mTORC1 signaling 
stimulation contributes to the Arf6 promitogenic activity [129].  
3.3. Control of mTOR signaling in response to energy stress 
AMPK (the AMP-activated protein kinase, also known as PRKAB1) is activated under the 
low level of intracellular ATP and found in all eukaryotes. It was initially identified as a 
serine/threonine kinase that negatively regulates several key enzymes of the lipid anabolism 
[130]. At present, AMPK is considered to be the major energy-sensing kinase that activates a 
whole variety of catabolic processes in multicellular organisms such as glucose uptake and 
metabolism, while simultaneously inhibiting several anabolic pathways, such as lipid, 
protein, and carbohydrate biosynthesis (reviewed in [130]). AMPK is upregulated under 
energy stress conditions in response to nutrient deprivation or hypoxia when intracellular 
ATP level decreases and AMP increases [131]. In response, AMPK turns on ATP generating 
pathways while inhibiting ATP consuming functions of the cell [131]. AMPK functions as 
heterotrimeric kinase complex, which consists of a catalytic (α) subunit and two regulatory 
(β and γ) subunits. Upon energy stress, AMP directly binds to tandem repeats of 
crystathionine-β-synthase (CBS) domains in the AMPK γ subunit [132]. Since the ratio of 
AMP to ATP represents the most accurate way to precisely measure the intracellular energy 
level, both AMP and ATP are able to oppositely regulate the activity of AMPK. While AMP 
binding to the γ–subunit allosterically enhances AMPK kinase activity and prevents the 
dephosphorylation of T172 [133], ATP is known to counteract the activating properties of 
AMP [130]. Although ADP does not allosterically activate AMPK, it also binds to AMPK 
and enhances phosphorylation at T172 [134, 135]. The phosphorylation of the activation loop 
T172 is absolutely necessary for AMPK activation. At present, several AMPK-
phosphorylating kinases have been identified. In addition to the ubiquitously expressed and 
constitutively active kinase LKB1, Ca2+-activated Ca2+/calmodulin-dependent kinase kinase β 
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(CaMKKβ) [136] and transforming growth factor β-activated kinase-1 (TAK1) are both 
known as AMPK activators. Genetic and biochemical studies in worms, flies, and mice have 
identified the serine/threonine liver kinase B1 (LKB1) as major kinase phosphorylating the 
AMPK activation loop at T172 residue, under conditions of energy stress [130]. Within the 
TOR signaling pathway, LKB1 dependent activation of AMPK inhibit mTORC1 activity by 
two ways (Figure 4). Firstly, AMPK directly phosphorylates the TSC2 on S1387 and T1227 
[2, 64, 70, 87, 137, 138]. AMPK phosphorylation of TSC2 has also been reported to act as a 
primer for the phosphorylation and enhancement of TSC2 function by glycogen synthase 
3(GSK3). GSK3β dependent phosphorylation of TSC2 on S1341 and S1337 stimulates its 
GAP activity towards Rheb, leading to the inhibition of mTORC1 [138]. It is possible that 
GSK3β cooperates with AMPK to fully activate the GAP activity of TSC2. The second, TSC2 
independent mechanism by which AMPK can signal to mTORC1, [45] is a direct 
phosphorylation of Raptor at two highly conserved residues — S722 and S792. These 
phosphorylation events induce Raptor direct binding to 14-3-3 protein, which leads to a 
suppression of mTORC1 kinase downstream activity [45]. Therefore, mTORC1 itself serves 
as an AMPK substrate for inhibiting phosphorylation.  
3.4. mTOR signaling regulating by hypoxia 
mTOR signaling pathway is strictly regulated by hypoxia [139, 140], since the sufficiency of 
oxygen is also essential for cellular metabolism. Hypoxia inhibits mTORC1 signaling via 
multiple signal pathways, two of them being mediated through activation of the TSC1/TSC2 
complex (Figure 4). First, activation of AMPK by hypoxia can enhance TSC complex 
function. Particularly, it was shown, that brief hypoxia exposure prevents insulin-mediated 
stimulation of mTORC1 and phosphorylation of its targets p70S6K and 4E-BP1 [139]. Under 
these conditions mTOR suppression is mediated through a HIF1α (hypoxia-inducible factor 
1α)-independent pathway involving AMPK-dependent activation of TSC1/TSC2 [2, 87, 141]. 
Second way includes the upregulation of TSC1/TSC2 through transcriptional regulation of 
stress-induced protein REDD1 (Regulated in Development and DNA damage responses, 
also known as DDIT4 or RTP801) [142, 143]. This response is mediated in part through a 
mechanism that involves HIF1α, a transcription factor that is stabilized under hypoxic 
conditions and drives the expression of several genes, including REDD1. Induction of 
REDD1 can activate the TSC1/2 complex by competing with TSC2 for 14-3-3 proteins 
binding [142, 144]. Thus, increased REDD1 levels that occur following exposure to hypoxia 
prevent the inhibitory binding of 14-3-3 to TSC2 [144], which eventually leads to the 
inhibition of mTORC1 signaling. Therefore inhibitory effect of REDD1 on mTOR signaling 
seemed to be dependent on the presence of the TSC1/2 complex, but independent on the 
LKB1-AMPK signaling [142, 145, 146]. However, most recent studies proposed that hypoxia 
and the LKB1-AMPK signaling are highly interrelated at least in some type of cells [140]. In 
response to prolonged hypoxia, REDD1 expression was enhanced by AMPK activation, 
leading to the inhibition of mTOR pathway. Indeed, it was demonstrated that prolonged 
hypoxia induced ATP depletion and eventually activate AMPK [140]. Taken together, under 
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hypoxic stress, the inhibition of mTOR activity by REDD1 activation may be mediated either 
through AMPK-independent or -dependent mechanisms. 
Hypoxia may also downregulate mTORC1 through proteins that hinder the the Rheb–
mTOR interaction. The PMl (promyelocytic leukaemia tumour suppressor) has been found 
to bind mTOR during hypoxia and inactivate it via sequestration in nuclear bodies [147]. 
Likewise, the hypoxia-inducible proapoptotic protein BNIP3 (BCl2/adenovirus E1B 19 kDa 
protein-interacting protein 3) was found to regulate mTOR by direct association with Rheb 
[148]. (Reviewed in [149]).  
 
 
Figure 4. mTORC1 regulation in response to energy deprivation and hypoxia. Low cellular energy 
levels (conveyed by AMP) and hypoxia activate AMPK, which represses mTORC1 both through direct 
negative phosphorylation of TSC2 and through Raptor inhibition. LKB1, CaMKK and TAK1 are known 
as AMPK activators. AMPK- and GSK3β-mediated phosphorylation of the TSC1/2 complex positively 
regulates the GAP activity of TSC2 towards Rheb, abrogating its stimulative activity towards mTORC1. 
Under hypoxic stress, the inhibition of mTOR activity could be mediated by REDD1 either through 
AMPK-independent or -dependent mechanisms. Hypoxia-inducible proapoptotic protein BNIP3 is 
reported to regulate mTOR by direct binding to Rheb, while PML can binds mTOR and inactivate it 
through sequestration in nuclear bodies. 
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4. Signaling downstream of mTOR 
4.1. TORC1 regulates translation machinery 
The protein synthesis stimulation and the inhibition of autophagy are two mostly known 
biological outputs controlled by this pathway under the favorable conditions, such as 
nutrient and oxygen availability. By sensing the presence of growth factors and the 
sufficiency of nutrients, activated mTORC1 mediates the signals to various components of the 
translation initiation machinery through direct or indirect phosphorylation events [22]. 
Several data also evidence that mTOR regulates the synthesis of many classes of lipids (such 
as phosphatidylcholine, phosphatidylglycerol, and sphingolipids, unsaturated and saturated 
fatty acids) that are required for membrane biosynthesis and energy storage (For the detailed 
review see [150]. Since the best characterized effectors of mTOR signaling are proteins 
controlling the translational initiation machinery it is important to understand how mTORC1 
signal transduction pathways contribute to protein synthesis regulation (reviewed in [151]).  
The earliest identified and best-studied mTORC1 targets are S6K kinases (p70 ribosomal 
protein S6 kinase 1 and 2) and 4EBP1 (eIF4E binding protein 1); both proteins involved in 
the translation initiation process [152] (Figure 5A). Protein synthesis is one of the most 
energy consuming processes within the cell and translation rates are strictly regulated 
mostly through modification of the eukaryotic initiation factors (eIFs). In eukaryotes, several 
mRNAs are translated in a cap-dependent manner. The cap structure, m7GpppN (where N 
is any nucleotide), is present at the 5’ terminus of the majority cellular eukaryotic mRNAs 
(except those in organelles) [153]. The cap structure is bound by the eIF4F (eukaryotic 
initiation factor 4F) complex, which contains three initiation factors — the mRNA 5’ cap-
binding protein eIF4E, an ATP-dependent RNA helicase eIF4A and a large scaffolding 
protein eIF4G, which provides docking sites for the other proteins. Briefly, to assemble the 
eIF4F complex, eIF4E binds the 5′ cap and recruits eIF4G and eIF4A. eIF4A along with eIF4B 
acts to unwind the mRNA 5’ secondary structure to facilitate ribosome binding [153]. It is 
especially essential, since stable secondary structures are often found in the 5′ UTR of 
specific mRNA species, many of which encode proteins that are involved in promoting cell 
growth and proliferation, and significantly suppress their translation efficiency [154]. As the 
translation preinitiation complex is recruited near the 5′ end of mRNA, this requires the 
structured UTR to be ‘linearized’ — not only for the initial binding of the 40S ribosome but 
also for subsequent searching for the downstream initiation codon. Although eIF4A alone 
exhibits low levels of RNA helicase activity the last one is substantially stimulated by its 
regulatory cofactor, eIF4B. Thus, eIF4B enhances the affinity of eIF4A binding to ATP, 
which, in turn, increases the processivity of the eIF4A helicase function [155]. eIF4G recruits 
the small ribosomal subunit to the mRNA (and the poly(A)-binding protein, PABP) through 
the ribosome associated large multisubunit factor eIF3. As a result the assembly of the 48S 
translation preinitiation complex takes place, allowing for the ribosome scanning and 
translation initiation [22, 26]. The translation initiation factors and cofactors that are 
regulated by mTORC1 signaling include eIF4G, eIF3, eIF4B, eIF4E and 4EBP1, of which 
4EBP1 is considered to be the most well-known mTORC1 direct effector protein. 
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eIF4G serving as a modular scaffold for the translation preinitiation complex formation, is 
phosphorylated in response to growth factor stimuli at multiple sites, some of which are 
dependent on mTORC1. These sites are clustered in a hinge region of eIF4G that joins two 
structural domains, and it has thus been predicted that the modification might induce 
conformational changes in the protein that affect its activity [22]. Nevertheless, the precise 
molecular mechanism by which eIF4G phosphorylation regulates its function remains to be 
determined. Regulation of the mRNA cap binding protein eIF4E is mediated mainly in two 
ways, firstly, through phosphorylation at S209 in its C-terminus by MAP kinase signaling 
integration kinases 1 and 2 (Mnk1/2) [156] and, secondly, through the sequestration by 
small, heat stable phosphoproteins termed 4E-binding proteins, 4E-BPs [153] belonging to 
the 4E-BPs translation repressors family. One of these proteins, 4E-BP1 is a direct mTORC1 
phosphorylation target. In quiescent cells, hypophosphorylated 4EBP1 binds tightly to 
eIF4E. As 4EBP1 and eIF4G share the same eIF4E-binding motif 4EBP1 competes with eIF4G 
for an overlapping binding site on eIF4E, and prevents eIF4G from interacting with eIF4E. 
On mTORC1 activation, hyperphosphorylated 4EBP1 dissociates from eIF4E, allowing for 
the recruitment of eIF4G and eIF4A to the 5’ end of an mRNA. Thus, the effects of 4E-BP1 on 
protein translation are not limited to switching ‘off ’ or ‘on’ protein synthesis; they can also 
alter the range of nascent proteins by mediating a switch between cap-dependent and cap-
independent translation. Indeed, during specific stress conditions, such as nutrient 
depletion, hypoxia or metabolic stress, the cell can reduce the activity of mTORC1, resulting 
in the cessation of cap-dependent translation and the concomitant promotion of cap-
independent translation of essential pro-survival factors. Rapamycin inhibits mTORC1-
dependent 4E-BP1 phosphorylation, stimulating the interaction between eIF4E and 4E-BP1, 
what leads to cap-dependent translation inhibition [157].  
Control of the 4E-BPs by mTOR 
Upon the stimulation (by growth factors, mitogens and hormones), human 4E-BP1 is 
phosporylated at 7 sites, 4 of which are involved in mTOR signaling [157, 158]. These are 
T37, T46 and T70, and S65. The 4E-BP1 phosphorylation is proceeded in a hierarchical 
manner (first T37 and T46, then T70 and last S65) [157]. S65 and T70 are located near the 
eIF4E-binding site. Often phosphorylation of these residues is stimulated by insulin in a 
rapamycin-sensitive manner. Some data evidence that phosphorylation of S65 is required 
for release of eIF4E from 4E-BP1, however the role of phosphorylation of this site is unclear 
[159]. Molecular dynamics findings [160] and earlier biophysical data suggest that 
phosphorylation of S65 and T70 is insufficient to bring about release from eIF4E. 
Phosphorylation of both S65 and T70 depends upon the prior phosphorylation of the N-
terminal threonines, and modification of T46 is considered to be essential for 
phosphorylation of T37 [157, 161]. The phosphorylation of T70 and S65 in human 4E-BP1 
depends upon a further site, S101 [162]. The phosphorylation of the N-terminal threonin 
residues in 4E-BP1 depends upon a certain sequence in the N-terminus, which includes the 
Arg-Ala-Ile-Pro (‘RAIP’ motif) [91, 163]. This phosphorylation is not significantly influenced 
by TOS motif inactivation and according to some data is rather insensitive to rapamycin 
[158]. This suggests that it could be mediated independently of mTORC1. However, several 
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data evidence that phosphorylation is mediated by mTORC1: (i) it is inhibited by starvation 
of cells for amino acids; (ii) it is activated by Rheb; (iii) it is suppressed by TSC1/2; (iv) it is 
sensitive to inhibitors of the kinase activity of mTOR and (v) it is decreased in cells in which 
mTOR levels have been knocked down [158]. Therefore, further study of this process needs 
to clarify the molecular mechanisms of mTOR downstream signaling. 
Control of the S6Ks by mTOR 
Another important target of mTORC1 is the S6 kinases family, including S6K1 and S6K2. 
Ribosomal protein S6 (rpS6) is highly phosphorylated protein containing at least five 
phosporylating sites in its C-terminus. There are two main classes of protein kinases which 
are responsible for rpS6 phosphorylation in vitro, namely the p70 S6 kinases (S6Ks) and the 
p90 ribosomal protein S6 kinases, also known as RSKs [164, 165], (reviewed in [151]). The 
observed sensitivity of rpS6 to rapamycin lead to the speculation that S6K are responsible 
for rpS6 phosphorylation as their activation is mediated by mTOR. Unlike S6Ks, the RSKs 
are not influenced by rapamycin since they are known to be activated through the classical 
MAP kinase (ERK) pathway (see below). There are two similar S6 kinase proteins, S6K1 and 
S6K2, in mammals [166], which show 70% of amino acid homology. Each p70S6K gene 
encodes two distinct proteins due to alternative splicing of the mRNAs. Several data 
confirm that activation of both the S6K1 and S6K2 are regulated by mTORC1 [118, 167, 168]. 
S6K1, which was discovered earlier than S6K2, is ubiquitously expressed and appears to be 
more critical for the control of cell growth. S6K1 can be activated by a wide variety of 
extracellular signals and is known as the major rpS6 kinase in mammalian cells and key 
player in the control of cell growth (cell size) and proliferation [169, 170].  
Earlier it was thought that activated S6K1 regulates translation of a class of mRNA 
transcripts that bear a 5’-terminal oligopolypyrimidine (5’-TOP). Particularly, it was shown 
that S6K1 phosphorylates eIF4B on S422, which is located in the RNA binding region that is 
necessary for promoting the helicase activity of eIF4A [171]. Few data indicate that eIF4B 
phosphorylation by S6K1 is both sufficient and necessary for its recruitment to the 
translation preinitiation complex [172]. However, there are also some data that disprove this 
model. In S6K1/2–/– cells, 5’-TOP mRNA translation is intact and still rapamycin-sensitive 
[173]. These results are in concordance with earlier data showing that mitogenic-stimulated 
or amino acid dependent 5’-TOP mRNAs translation is dependent on PI3K mediated 
signaling, and does not require S6K1 activity and ribosomal protein S6 phosphorylation 
[174, 175]. Instead, a role for the S6 kinases in controlling the cell size has been suggested as 
deletion of S6K leads to animal size decrease [173]. Studies performed on ‘knock-in’ mice in 
which all sites phosphorylated by the S6 kinases were mutated also indicated a role for S6 
phosphorylation in cell growth [176]. These knock-in cells still demonstrated faster rates of 
protein synthesis at the same time being decreased in size. This could be explained by 
elevated access of the S6K to other substrates involved in translation, such as eIF4B and 
eEF2 kinase (see below) [151].  
Another pool of data connecting S6K1 activity and translation initiation occurs from the 
study of potential tumor suppressor, Programmed cell death 4 (PDCD4) protein (Figure 
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5A). PDCD4 binds to eIF4A and is thought to inhibit its helicase activity [177]. PDCD4 is 
also thought to prevent eIF4A from incorporating into the eIF4F complex by competing with 
eIF4G for eIF4A binding [178]. S6K1 phosphorylates PDCD4 on S67 in response to growth 
factor stimulation resulting in its subsequent degradation through the ubiquitin ligase 
βTrCP101. Therefore, S6K1-dependent phosphorylation of PDCD4 prevents the inhibitory 
effect of PDCD4 towards eIF4A helicase function within the eIF4F complex. 
Recent data give new evidence on interconnection of the mTOR/S6K1 pathway and translation 
preinitiation complex assembly [172, 179]. Under the poor growth conditions, S6K1 but not 
mTORC1 binds with multisubunit initiation factor eIF3 that was identified as a dynamic 
scaffold for mTORC1 and S6K1 binding [172] (Figure 5B). Upon growth factors or nutrients 
availability, the mTORC1 is recruited to eIF3 and phosphorylates S6K1. Based on polysome 
analysis and cap-binding assays, it is thought that the mTORC1–eIF3 complex associates with 
the mRNA 5′ cap, bringing mTORC1 into proximity with 4EBP1. Phosphorylation of S6K1 at 
T389 leads to its dissociation from eIF3. T389-phosphorylated S6K1 binds to PDK1 (Figure 5A), 
which phosphorylates S6K1 at T229. The fully activated S6K1 is able to phosphorylate eIF4B 
and S6. Phosphorylation of eIF4B by S6K1 at S422 promotes its association with eIF3 [172, 180]. 
The interaction of mTOR with eIF3 also strengthens the association between eIF4G and eIF3 
[181]. Described interactions cooperate to enhance the assembly of translation initiation 
complex and facilitate cap-dependent translation.  
The S6 kinases are activated by phosphorylation at multiple sites. Several of them lie within 
the C-terminus, while two others lay immediately C-terminal to the catalytic domain. One of 
these, T389 in the shorter form of S6K1, which is located at a hydrophobic motif 
carboxyterminal to the kinase domain, is directly phosphorylated by mTOR as part of the 
mTORC1 complex [182, 183]. Phosphorylation here is required for the consequent 
phosphorylation of S6K1 by PDK1 at a T229 in the activation loop of the catalytic domain. 
Phosphorylation at T229 allows full activation of S6K1. S6K2 is likely regulated in a similar 
manner. Both S6K1 and 2 contain a TOS motif within their N-terminus region, which interacts 
with Raptor, promoting phosphorylation of S6Ks by mTORC1 [184]. The phosphorylation 
within the C-terminal region seems to open access to the sites T389/T229, phosphorylation of 
which provides the complete activation. It is not known exactly which kinase is responsible for 
C-terminal phosphorylation sites. Nevertheless mTOR also indirectly contributes to the 
phosphorylation of the C-terminal sites. A motif RSPRR exists in this region probably plays a 
significant role in the inhibitory effect of the C-terminal region. It has been speculated that a 
negative S6K1 regulator binds S6K via this motif and that mTOR could broke this binding 
[184]. The C-terminal region of S6K1 also determines whether S6K1 can be phosphorylated by 
mTORC2. Mutant S6K1 with deletion of this region is a substrate for mTORC2 [185]. Some 
data indicate that for S6K1 activation, mTOR can directly phosphorylate S371 in vitro, and this 
event modulates T389 phosphorylation by mTOR [186, 187]. 
In addition to the discussed above mTORC1 targets, S6Ks and 4E-BP1, both of which 
modulate translation initiation, mTOR signaling also regulates the translation elongation 
process through the phosphorylation of eukaryotic elongation factor 2 (eEF2). eEF2 is a GTP 
binding protein that mediates the translocation step of elongation [188]. eEF2 is 
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phosphorylated at T56 within the GTP-binding domain and this phosphorylation impedes its 
ability to bind the ribosome, thus inhibiting its function [188, 189]. Insulin and other stimuli 
induce the dephosphorylation of eEF2, and this effect is blocked by rapamycin, indicating 
that this effect is also mediated through mTOR [190]. The eEF2 phosphorylation function is 
attributed to a highly specific enzyme called eEF2 kinase (eEF2K) [190]. Phosphorylation of 
eEF2 at T56 by eEF2 kinase impedes the eEF2 binding of to the ribosome and the 
translocation step of the elongation [188]. The calcium/calmodulin-dependent protein kinase 
eEF2K is an atypical enzyme since the sequence of its catalytic domain differs substantially 
from that of other protein kinases, and it is not a member, e.g., of the main Ser-Thr-Tyr kinase 
superfamily [191]. The C-terminal half of the eEF2K polypeptide contains several sites of 
phosphorylation including the binding site for the substrate eEF2 at the C-terminus [192]. 
mTOR negatively regulates eEF2 kinase and consequently activates eEF2. mTOR is 
considered being able to phosphorylate 3 sites, as was determined by their rapamycin- and/or 
amino-acid starvation sensitivities [188, 193]. S366 in the C terminus of the catalytic domain 
has been identified as the site being phosphorylated by S6K and by p90RSK [190]. The 
phosphorylation at S359 has been shown to be also regulated in a rapamycin-sensitive 
manner in response to insulin-like growth factor 1 (IGF1) and inactivates eEF2K [194], but the 
kinase responsible for this phosphorylation remains to be determined. Recently, a novel 
phosphorylation site located immediately adjacent to the CaM-binding site in eEF2K that is 
regulated markedly in response to insulin in an mTOR dependent manner has been 
identified. This site (S78) is not known to be phosphorylated by any known protein kinase in 
the mTOR pathway. Phosphorylation at this third site also causes the inactivation of eEF2 
kinase, in this case by inhibiting the binding of CaM, which binds immediately C-terminal to 
S78 [193]. eEF2K is thought to be a target of signaling from mTOR independently of other 
known targets of this pathway, which implies the existence of a novel (probably mTOR-
controlled) protein kinase that could acts upon S78 in eEF2K. These data provide a molecular 
mechanism by which mTOR could regulate peptide chain elongation. 
Since the protein synthesis depends on the amount of ribosomes and transfer RNAs (tRNAs) 
it is important to know that mTOR signaling also contributes to the regulation of tRNA 
production, promotion of rRNA synthesis and ribosome biogenesis. Thus mTOR signaling 
tightly regulates transcription of ribosomal RNAs (rRNAs) and tRNAs by RNA polymerases 
I and III [195]. mTOR can associate with general transcription factor III C (TFIIIC) and 
relieve its inhibitor Maf1, leading to increased tRNA production. mTORC1 activity also 
promotes association between transcription initiation factor 1A (TIF-1A) and polymerase I 
(PolI), thereby promoting rRNA synthesis [35]. The activity of several other transcription 
factors, such as signal transducer and activator of transcription-1 and -3 (Stat-1 and Stat-3) is 
also suggested to be regulated by mTORC1-mediated phosphorylation in a rapamycin-
sensitive manner [196]. 
4.2. TORC1-mediated repression of autophagy 
Autophagy is a lysosomal-dependent cellular degradation process that generates nutrients 
and energy to maintain essential cellular activities upon nutrient starvation. A term  
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Figure 5. mTORC1 downstream signaling and translation regulation.  
A. mTOR phosphorylates two major targets: 4E-BP1 and S6Ks. Hypophosphorylated 4E-BP1 binds 
tightly to eIF-4E, thereby preventing its interaction with eIF-4G and thus inhibiting translation. 
Phosphorylated 4E-BP1 is released from eIF-4E resulting in the recruitment of eIF-4G to the 5′-cap, 
and thereby allowing translation initiation to proceed. Phosphorylation of p70S6K stimulates its activity 
towards several substrates, including 40S ribosomal protein S6, translation initiation factor eIF-4B, 
elongation factor kinase eEF2K, and PDCD4 protein. Following S6K-mediated phosphorylation, eIF-4B 
is recruited to the translation pre-initiation complex and enhances the RNA helicase activity of eIF-4A. 
S6K1dependent phosphorylation of PDCD4 prevents its inhibitory effect towards eIF-4A helicase. 
mTORC1 also contributes to the translation elongation through the regulation of eEF2. mTOR 
negatively regulates eEF2 kinase (either directly or via p70S6K activation) and thereby activates eEF2. 
mTOR signaling also contributes to the regulation of tRNA production, promotion of rRNA synthesis 
and ribosome biogenesis activating TFIIIC and promoting the association between transcription 
initiation factor 1A and polymerase I respectively.  
B. In the absence of extracellular stimuli, S6K1 is associated with eIF3 while 4E-BP1 binding to eIF-4E 
prevents its interaction with eIF-4G and thus inhibiting translation. In response to extracellular stimuli, 
such as growth factors or nutrients, the mTOR complex is recruited to eIF3 to phosphorylate S6K1 and 
4E-BP1. Phosphorylation and activation of S6K1 leads to its dissociation from eIF3. Activated S6K1 then 
phosphorylates eIF4B and S6. Phosphorylation of eIF-4B 2 promotes its association with eIF3. mTOR 
also stimulates the association between eIF3 and eIF-4G. 
 
Protein Phosphorylation in Human Health 26 
autophagy appeared from Greek “auto” (self) and “phagy” (to eat), refers to an 
evolutionarily conserved, multi-step lysosomal degradation process in which a cell degrades 
long-lived proteins and damaged organelles. Three forms of autophagy have been 
identified, namely macroautophagy, microautophagy and chaperone-mediated autophagy 
that differ with respect to their modes of delivery to lysosome and physiological functions 
[197]. Macroautophagy (hereafter autophagy) is the major regulated catabolic mechanism 
that involves the delivery of cytosolic cargo sequestered inside specific intracellular double-
membrane vesicles, called autophagosomes to the lysosomal compartment and subsequent 
fusion with lysosomes to form single-membrane-bound autophagolysosomes, in which the 
sequestered material is degraded by acidic lysosomal hydrolases. On one hand, autophagy 
is crucial for cell survival under extreme conditions through degradation of intracellular 
macromolecules, which provides the energy required for minimal cell functioning when 
nutrients are deprived or scarce. Also, autophagy-mediated elimination of altered cytosolic 
constituents, such as aggregated proteins or damaged organelles, preserves cells from 
further damages, indicating that autophagy plays a protective role in early stages of cancer 
[198]. On the other hand, autophagy plays a death-promoting role as type II programmed 
cell death (type II PCD), compared to apoptosis (type I PCD), as a bona fide tumor 
suppressor mechanism in cancer [199]. 
The ability of mTORC1 to regulate autophagy is as highly conserved as well as the process 
of autophagy itself. AMPK has been indicated as a main upstream regulator of mTORC1 
mediated autophagy inhibition.  
The mechanism by which TORC1 negatively regulates the autophagic machinery has first 
been described in yeast. Genetic screenings for autophagy defective mutants led to the 
identification of more than 30 essential autophagy-related genes (Atg).These proteins can be 
classified into several groups depending on their function and interdependency. Most 
upstream is a protein complex that comprises the serine/threonine kinase Atg1, as well as 
two accessory proteins Atg13 and Atg17. In mammals, two homologs of Atg1, 
uncoordinated 51-like kinase 1 (ULK1) and ULK2 have been identified. Accumulating 
evidence suggests that ULK1 is a key regulator of autophagy initiation. ULK1 is directly 
phosphorylated by TORC1 [200-202]. Recently, it has also been shown that mTORC1-
mediated phosphorylation of ULK1 impairs its activation by AMPK and results in an overall 
decrease in autophagy [203]. ULK1 and ULK2 are found in a stable complex with 
mammalian autophagy-related protein 13 (mAtg13), the scaffold protein FAK-family 
interacting protein of 200 kDa (FIP200) [204] [201] and Atg101, an additional binding partner 
of Atg13 that has no ortholog in yeast [205]. In contrast to yeast, the composition of this 
complex does not change with the nutrient status. Several data evidence that the 
phosphorylation status within the Ulk1/2-Atg13-FIP200 complex dramatically changes with 
the nutrient availability. Under rich growth conditions, mTORC1 associates with the Ulk1/2-
Atg13-FIP200 complex, via direct interaction between Raptor and Ulk1/2 (37). The active 
mTOR phosphorylates Atg13 and Ulk1/2 [201], thereby downregulating Ulk1/2 kinase 
activity and suppressing autophagy (Figure 6). In response to starvation, the mTORC1-
dependent phosphorylation sites in Ulk1/2 are rapidly dephosphorylated by yet unknown 
phosphatases, what stimulates Ulk1/2 autophosphorylation and phosphorylation of both 
 
Protein Phosphorylation as a Key Mechanism of mTORC1/2 Signaling Pathways 27 
Atg13 and FIP200. Several serine and threonine residues in human Ulk1 whose 
phosphorylation was decreased after starvation have been recently identified from which 
S638 and S758 have been proposed to be most probable mTORC1 negative phosphorylation 
sites [203, 206]. Ulk1/2 autophosphorylation and following FIP200 and Atg13 
phosphorylation in turn leads to translocation of the entire complex to the pre-
autophagosomal membrane and to autophagy induction [200, 201, 205]. However, the 
functional relevance of Ulk1/2-mediated phosphorylation of Atg13 and FIP200 for this 
recruitment and the relevant phosphorylation sites has not been verified yet. Interestingly, 
another Ulk1-dependent phosphorylation site in human Atg13 (S318) has been identified 
recently [207]. The authors of that study could show that the Hsp90-Cdc37 chaperone 
complex selectively stabilizes and activates Ulk1. 
 
Figure 6. mTORC1 downstream signaling and autophagy regulation. Ulk1 and Ulk2 form a stable 
complex with Atg13, FIP200 and Atg101. Under fed conditions mTORC1 phosphorylates Ulk1/2 and 
Atg13, thereby inhibiting the Ulk1/2 kinase activity and complex stability. In response to starvation, the 
mTORC1-dependent phosphorylation sites in Ulk1/2 are rapidly dephosphorylated, and Ulk1/2 
autophosphorylates and phosphorylates Atg13 and FIP200 resulting in translocation of the entire 
complex to the pre-autophagosomal membrane and autophagy induction. Alternatively, Ulk1/2 is 
phosphorylated by AMPK and thereby activated. In addition, AMPK indirectly leads to the induction of 
autophagy by inhibiting mTORC1 through phosphorylation of Raptor or TSC2. 
In yeast, autophagosomes originate from a single preautophagosomal structure. Although 
an equivalent structure seems to be absent from mammalian cells, a special subdomain in 
the endoplasmic reticulum (ER) termed the “omegasome” has been suggested as a putative 
origin of autophagosomes. This structure is enriched in PI(3)P, a product of the 
phosphatidylinositol 3-kinase (PI3K). A hierarchical analysis of the mammalian Atg proteins 
could recently confirm the recruitment of Ulk1 proximal to these omegasomes [208]. The 
translocation of Ulk1, presumably in a complex with Atg13 and FIP200, is the initial step of 
autophagosome biogenesis and is completely abrogated in FIP200–/– cells [208]. The 
subsequent recruitment of the PI3K depends on Ulk1 and its kinase activity [208]. Recently, 
two groups found evidence for the mechanism by which Ulk1 and Ulk2 in turn negatively 
regulate mTORC1 signaling. Particularly, the phosphorylation of Raptor at numerous sites 
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was strongly enhanced after overexpression of Ulk1. Interestingly, one of these residues 
(T792) is the abovementioned effector site through which AMPK negatively regulates 
mTORC1 activity [45]. The multiple Ulk1-dependent phosphorylation of Raptor either 
results in direct inhibition of mTORC1 kinase activity [209], or interferes with Raptor-
substrate interaction [210], thus finally leads to reduced phosphorylation of mTORC1 
downstream targets. 
Apart from mTOR, Ulk1/2 is phosphorylated (probably on S317 and S777 or S555 according 
to different studies) by AMPK under glucose starvation and thereby activated [112, 203, 211, 
212]. Under nutrient sufficiency phosphorylation of ULK1 S758 by active mTORC1 disrupts 
ULK1 interaction with, and hence activation by, AMPK [203]. Although the data concerning 
the role of ULK1/2 certain sites phosphorylation is rather discrepant it is clear that in 
mammals, phosphorylation of ULK1 by AMPK is strongly required for ULK function in the 
response to nutrient deprivation. Therefore, AMPK could control ULK1 via a two-pronged 
mechanism, ensuring activation only under the appropriate cellular conditions – firstly, by 
direct phosphorylation and secondly, by suppression of mTORC1-mediated ULK1 
inhibition [212]. Several studies demonstrated that Ulk1 in addition directly interferes with 
mTORC1 downstream signaling and negatively regulates S6K1 activity, both in Drosophila 
and mammalian cells [213]. Taken together these data evidence that mTOR subnetwork 
occupy the key position in autophagic pathways.  
5. Signaling up and downstream of mTORC2 
In contrast to mTORC1, very little is known about the upstream regulation of TORC2. 
Rapamycin–FKBP12 complex does not bind directly to mTORC2, but long-term rapamycin 
treatment disrupts mTORC2 assembly in ~20% of cancer cell lines through an unknown 
mechanism [56]. It remains to be determined why rapamycin-mediated inhibition of 
mTORC2 assembly only occurs in certain cell types. One hypothesis suggests that some 
mTORC2 subunits could prevent the binding of rapamycin/FKBP12 complex to the mTOR 
FRB domain by the competing mechanism (reviewed in [62]). However, there are no enough 
data to support this model. 
It seems that mTORC2 is activated in response to growth factors but is insensitive to 
nutrients and energetic stress, [214]. Thus, like TORC1, TORC2 can be stimulated by growth 
factors through PI3K [3]. Consequently, treatment with PI3K inhibitors can inhibit TORC2-
mediated target phosphorylation [85]. Thus it was suggested that mTORC2 lies downstream 
of PI3K signaling [85]. Rheb which is known as a key upstream activator of mTORC1 
showed negative and indirect effect on the regulation of mTORC2 both in Drosophila and 
mammalian cells [59]. Some data pointed on TSC1-TSC2 function in mTORC2 regulation 
[92]. Moreover, the TSC1/TSC2 complex was found to physically associate with mTORC2, 
but not with mTORC1. The molecular mechanism through which the TSC1/TSC2 complex 
promotes mTORC2 activation is unclear. It is also currently unknown whether some 
pathways that regulate TSC1/TSC2 ability to inhibit mTORC1, also influence on mTORC2 
activation. 
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The best-characterized target of mTORC2 is AKT, which is phosphorylated at S473 upon 
TORC2 activation [53, 58, 85]. Numerous studies attempted to identify the crucial kinase(s) 
(often referred to as PDK2) responsible for the phosphorylation of S473 in Akt. Several 
enzymes are in the candidate list, including PDK1, integrin-linked kinase (ILK), Akt itself, 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and mTORC2 [215]. Since 
mTORC2 complex fulfills the role of the Akt S473 kinase, mTORC2 has been identified as 
the PDK2 [85]. Akt is a member of the AGC kinase family (see above), which also includes 
S6Ks, serum glucocorticoid-induced protein kinase (SGKs), RSKs, and PKCs [62, 216]. 
mTORC2 has been shown to phosphorylate AKT, SGK and PKC [85]. mTORC2 seems to 
regulate Akt by phosphorylation of its two different sites. The mTORC2-mediated Akt 
hydrophobic motif phosphorylation on the regulatory S473 site is dependent on growth 
factor signaling, whereas a basal activity of mTORC2 maintains the constitutive 
phosphorylation of Akt on T450 site in its turn motif [217]. This difference indicates that 
phosphorylation of the T450 and S473 sites on Akt by mTORC2 are separate events and 
might take place at different locations. It has been proposed that translocation of Akt to the 
plasma membrane coupled with its phosphorylation on T308 and S473 is a critical step in 
activation of Akt by growth factor signaling [217]. Phosphorylation of AKT on S473 
enhances the activation phosphorylation motif at T308, which is absolutely required for 
AKT activity. 
The major functions of mTORC2 include the regulation of cytoskeletal organization and the 
promotion of cell survival. If the last one is mediated apparently through AKT activation, 
the mechanisms, which realize mTORC2 function in cytoskeletal reorganization, are not 
obvious. Paxillin, which functions as a docking protein, localizing to the focal adhesions of 
adherent cells [218] has been shown to be highly phosphorylated at Tyr118. Knockdown of 
mTORC2 inhibited the phosphorylation of paxillin [3]. Rho, Rac and Cdc42, three best-
characterized members of the Rho family of small GTPases, were demonstrated to be 
involved in actin cytoskeleton assembly and disassembly [219]. It was reported that 
mTORC2 may function as upstream regulator of Rho GTPases to regulate the actin 
cytoskeleton [3].  
Interestingly, the TORC2-mediated activation of AKT places TORC2 upstream of TORC1 in 
the TOR signaling cascade. A most recent publication has highlighted a role for ribosomes in 
the activation of TORC2 [38]. The authors have found that active mTORC2 was physically 
associated with the ribosome, and insulin-stimulated PI3K signaling promoted mTORC2-
ribosome binding. Interaction of mTORC2 with NIP7 (nuclear import 7, a protein 
responsible for ribosome biogenesis and rRNA maturation) was shown to be required for 
full activation of mTORC2 by insulin. Noteworthy, inhibition of protein translation had no 
effect on mTORC2 activation, supporting the notion that mTORC2 is activated by the 
ribosome, but not translation. Ribosome associated mTORC2 displays kinase activity 
toward AKT in vitro. Inhibition of PI3K activity blocks the interaction between the ribosome 
and mTORC2, as well as inhibits mTORC2 activation in response to insulin, confirming that 
NIP7-ribosome assembly activates mTORC2 downstream from PI3K. It appears that the 
mTORC2 components, Rictor and/or Sin1, which are not found in mTORC1, interact with 
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the 60S subunit of ribosome. Interestingly, another study [220] has also recently reported the 
association of mTORC2 with the ribosome and proposed that the ribosomal association is 
important for the cotranslational phosphorylation of the AKT turn motif. These findings are 
coherent with very recent data that point on endoplasmic reticulum (ER), the cellular 
organelle highly enriched with ribosomes, as a major compartment of mTORC2 localization. 
Moreover, the signaling from growth factor does not change the ER localization of mTORC2 
as well as its translocation to the plasma membrane. Besides it was suggested that the 
mTORC2-dependent phosphorylation of Akt on S473 occurs on the surface of ER [37]. These 
observations raise many interesting questions regarding the regulation of TORC2 and its 
ribosomal interactions, but it also indicates that additional levels of interplay between 
TORC2 and TORC1 may exist, as both complexes are linked to the process of ribosome 
biogenesis. 
6. Crosstalk of mTORC1/2 and major cytokine signaling pathways 
6.1. mTORC1/2 and Ras-MAP kinases pathways 
Ras-Erk-RSKs 
In addition to the PI3K–Akt pathway, activation of Ras-MAPK signaling can also stimulate 
mTORC1 activity. The Ras–mitogen-activated protein kinase (MAPK) pathway is a key 
signaling pathway that is involved in the regulation of normal cell proliferation, survival, 
growth and differentiation. This pathway includes the whole number of kinases, being 
regulated through phosphorylation in consecutive order. The Ras–MAPK signaling network 
has been the subject of intense research because mutations in (or overexpression of) many of 
the signaling components from this pathway are a hallmark of several human cancers and 
other human diseases [221]. The Ras–ERK (extracellular signal-regulated kinase-1 and -2) 
pathway has an established role in regulating transcription [222], but a connection between 
this pathway and translational regulation is less clear. Over the past few years, mitogen 
activated Ras–ERK pathway has been shown to trigger the activation of mTORC1 signaling. 
This is mediated by ERK and RSK dependent phosphorylations of TORC1 pathway 
components. 
p90RSKs (also known as MAPKAP kinase 1 (mitogen-activated protein kinase-activated 
protein) kinase-1) are a family of Ser/Thr kinases that lies downstream of the Ras–MAPK 
cascade and has overlapping substrate specificity with Akt. The RSK isoforms are directly 
activated by ERK1/2 in response to growth factors, many polypeptide hormones, 
neurotransmitters, chemokines and other stimuli. RSKs phosphorylate several cytosolic and 
nuclear targets and they are involved in the regulation of different cellular processes, including 
cell survival, cell proliferation, cell growth and motility. Following the stimulation of cells with 
growth factors, RSKs are phosphorylated at multiple Ser and Thr residues by several kinases; 
these phosphorylation events are directly or indirectly initiated by the activation of the 
ERK/MAPK cascade [223]. Six different phosphorylation sites have been mapped in RSK1/2 
(and are conserved in RSK3/4), of which four have been shown to be important for their activity 
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(S221, S363, S380 and T573 in human RSK1). Following mitogen stimulation, ERK1/2 
phosphorylates T573 at the C-terminal domain (CTKD) activation loop of RSK, resulting in 
CTKD activation. ERK1/2 might also phosphorylate S363 (the turn motif) and T359 (unknown 
function) in the RSK linker region. The activated CTKD of RSK then autophosphorylates S380 in 
the hydrophobic motif, creating a docking site for PDK1. After binding, PDK1 phosphorylates 
the NTKD activation loop S221, leading to the complete activation of the protein and following 
phosphorylation of the substrates by the NTKD. The NTKD also phosphorylates S749 in the 
CTKD domain of RSK, differentially modulating the interaction of RSK isoforms with ERK1/2 
and thereby completing a sequence of coordinated phosphorylation events and protein–protein 
interactions that culminate in RSK activation and downstream signaling throughout the cell 
[224]. Other factors that have been shown to be involved in the activation of RSK include the 
p38 MAPK, the ERK5 MAPK and fibroblast growth factor receptor-3 (FGFR3). RSK was found 
to phosphorylate TSC2 at the C-terminus S1798 [225] and, to a lesser extent, the two conserved 
Akt sites (S939 and T1462) and inactivates its suppressor function, thereby promoting mTOR 
signaling and translation (Figure 7). RSK mediated phosphorylation of TSC2 is additive to AKT 
mediated inhibitory modifications of TSC2, but how these phosphorylation events lead to TSC2 
inhibition remains unclear. 
Erk1/2 kinase itself also impacts the mTORC1 regulation. Thus, a number of additional sites 
on TSC2 were found to be weakly induced by PMA [89], including an ERK consensus site 
S664. This site, and a second site on TSC2, S540, was independently found to be directly 
phosphorylated by ERK and to contribute to ERK-mediated activation of mTORC1 signaling 
[226]. Strikingly, phosphorylation of S540 and/or S664 by ERK was found to disrupt the 
association between TSC1 and TSC2. This effect was also detected following 
phosphorylation of the TSC1/TSC2 complex in vitro, suggesting that it is direct and does not 
require other proteins.  
In addition, it was recently shown that RSK also directly impacts the mTORC1 complex 
phosphorylating Raptor, and thereby promotes mTORC1 kinase activity [46]. RSK 
phosphorylates at least two evolutionarily conserved Raptor serine residues that lie within a 
region with no homology to known functional domains. Whereas S721 lies within a classical 
RSK consensus sequence (RXRXXpS/T), S719 is located within a minimal phosphoacceptor 
sequence (RXXpS) that was found to be sufficient in other RSK substrates, such as DAPK, c-
Fos, and CREB. Although the underlying molecular mechanism of this was not fully 
defined, this study provided new insights into Ras–ERK signals to mTORC1. As tumor 
promoting phorbol esters and some growth factors activate mTORC1 signaling 
independently of AKT, phosphorylation of Raptor by RSK might provide a mechanism to 
overcome the inhibitory effects of PRAS40 inhibitory phosphorylation of TSC2 at S664 and 
S1798, respectively [89, 226, 227]. Collectively, these data suggest that ERK signaling 
activates mTORC1 through multisite phosphorylation events by both ERK and its 
downstream target RSK. 
Erk1/2-RSK pathway also contributes to the mTORC1 downstream signaling, this includes 
RSK dependent in vivo and in vitro phosphorylation of eukaryotic translation initiation 
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factor-4B (eIF4B) and rpS6 [180]. Although early studies indicated S6K1 and S6K2 as the 
major rpS6 kinases in somatic cells [228, 229], the role of RSK in regulating site-specific rpS6 
phosphorylation and translation in somatic cells has been recently readdressed [230]. 
Particularly, in vitro and in vivo evidence suggests that S6Ks phosphorylate every site in 
rpS6, while RSK predominantly phosphorylates S235 and S236 [230]. Studies from 
S6k1/S6k2-knockout mice showed that there was minimal phosphorylation of rpS6 at 
S240/244, but there was persistent phosphorylation at S235/236 [173]. In accordance with this 
finding, RSK1 and RSK2 were shown to phosphorylate rpS6 on S235/236 in response to Ras–
MAPK-pathway activation, using an mTOR-independent pathway [230]. The RSK mediated 
S235/236 phosphorylation correlated with formation of the translation pre-initiation 
complex and increased cap-dependent translation, pointing that RSK provides an additional 
mitogen- and oncogene-regulated input that links the ERK pathway to the regulation of 
translation initiation [230]. Translation initiation factor-4B is also phosphorylated by RSK 
and S6K on S422 [171, 180]. Therefore, phosphorylation and regulation of eIF4B function by 
RSK and S6K exemplifies the convergence of two major signaling pathways that are 
involved in translational control. Together, these findings suggest that the mitogen-
activated Ras–ERK–RSK signaling module, in parallel with the PI3K–AKT pathway, 
contains several inputs to stimulate mTORC1 signaling. 
6.2. mTORC1 and TNFα-IKKβ-TSC1 pathway 
Although the activation of mTORC1 downstream of most cytokines including insulin and 
growth factors is likely to occur through the Akt and ERK signaling mechanisms described 
above, accumulating evidence suggests that other cytokines, such as tumor necrosis factor α 
(TNFα), can also induce mTORC1 activity. TNFα is a proinflammatory cytokine that is 
involved in many human diseases, including cancer [231, 232]. Early studies implicated the 
TNFα pathway in mTORC1 activation [233]. Recently, it has been shown that IKKβ 
(inhibitor of nuclear factor κB (NFκB) kinaseβ; also known as IKBKB), a major downstream 
kinase in the TNFα signaling pathway, can associate with and phosphorylates TSC1 at S487 
and S511, resulting in the inhibition of TSC1–TSC2 and, therefore, the activation of mTORC1 
[234]. Tsc1−/− mouse embryo fibroblasts expressing TSC1 mutants lacking these sites lose 
their responsiveness to TNFα for activation of mTORC1, whereas phosphomimetic mutation 
lead to a basal increase in mTORC1 signaling. Authors proposed a mechanism involving 
rapid dissociation of the complex and increased degradation of TSC1. However, the results 
suggest minimal effects on the stability of the TSC1–TSC2 complex, and the precise 
mechanism of acute complex inhibition by phosphorylation of these sites is not known. In 
certain human cancers, TNFα promotes vascular endothelial growth factor (vEGF) 
expression and angiogenesis through activated mTORC1 signaling as a result of IKKβ 
mediated suppression of TSC1 [234]. This has provided a plausible mechanism that could 
link inflammation to cancer pathogenesis. Moreover, TNFα also signals to AKT [231]. 
Activated AKT in turn induces IKKα (also known as CHUK), [232]. It has been shown that 
IKKα associates with mTORC1 in an AKT dependent manner [235]. Importantly, IKKα is 
required for efficient induction of mTORC1 activity by AKT in certain cancer cells [235, 236]. 
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It remains unclear, however, how the association of IKKα with mTORC1 can result in the 
activation of mTORC1.  
 
 
Figure 7. mTORC1 crosstalk with the major cytokine signaling pathways. MAPK pathway impinges 
on the mTORC1 signaling in a few ways. RSK phosphorylates TSC2 at the C-terminus and, to a lesser 
extent, the two conserved Akt sites thus inactivating its suppressive effect on mTORC1. RSK also 
directly impacts the mTORC1 complex by phosphorylation of Raptor and thereby upregulates mTORC1 
kinase activity. Besides, RSK phosphorylates the rpS6 and eIF-4B to promote cap-dependent translation 
in response to Ras–MAPK-pathway activation. ERK1/2 kinase contributes to the activation of mTORC1 
signaling through direct phosphorylation of TSC2 and probably through the disruption of the 
association between TSC1 and TSC2. Stress activated signaling pathway might also influence mTORC1 
signaling through TSC2 phosphorylation by p38-activated MAPKAPK2 kinase. IKKβ, a major 
downstream kinase in the TNFα signaling pathway, can associate with and phosphorylate TSC1 
leading to the inhibition of TSC1/TSC2 and, therefore, the activation of mTORC1. 
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7. Conclusion 
Maintenance of cellular energy homeostasis and life-sustaining activity requires their 
appropriately adaptation to the continually varying surrounding environment. This 
adaptation is provided by the differential expression of genes that is strictly controlled at the 
levels of transcription and translation. To provide the rapid response to the environmental 
cues cells switch vast number of intracellular signaling cascades that define the activity of 
key proteins responsible for transcription and translation regulation. This implies operative 
and directed changes in the activities of proteins mediating the signal transduction. 
Phosphorylation represents one of the most important intracellular regulatory molecular 
mechanisms since it provides the rapid and reversible activation or downregulation of 
protein activities. Not surprisingly, mTOR signaling network, which integrates and 
promotes the prompt respond to environmental changes is mainly regulated through this 
type of posttranslational modification. mTOR is known as a “switch master” that converts 
vast array of nutrient-, cytokine-, energy- and stress-sensitive signals into the alterations of 
cellular metabolism including protein and lipid biosynthesis and autophagy. Indeed such 
resources consuming processes as growth and proliferation could occur only under the 
conditions of nutrient and energy sufficiency. When energy or amino acids become limiting, 
cell growth needs to be restricted and protein production needs to be downregulated so that 
cells can use their limited resources to survive. mTORC1 contributes to overall cap-
dependent translation including initiation and elongation steps by several different 
pathways. Significantly, all of these pathways use phosphorylation as common molecular 
mechanism of regulation. Most of the proteins from mTOR-dependent pathways (for 
instance TSC2, Akt, S6K, etc.) contain multiple phosphorylating sites, which mediate 
stimulating or negative effect on their activity. Some of mTOR partners are characterized by 
the hierarchical mode of phosphorylation (rpS6, Akt as the examples), whereby each 
previous phosphorylation opens the opportunity for the subsequent ones. Interestingly, one 
certain site could serve as phosphorylation target for more than one kinase, therefore 
implementing the competitive mechanism of regulation (for instance, eIF4B S422). The 
complexity of mTOR signaling increases due to the presence of positive or negative 
feedback loops as well as crosstalk with other pathways. The number of reported 
phosphorylation sites throughout mTOR pathways constantly increases although the 
precise molecular meaning of several already discovered phosphorylation events remains 
unclear. This is also true to some molecular mechanisms of mTORC1 and especially 
mTORC2 functioning. About mTORC1 signaling, a number of issues remain unresolved. 
For example, aside from S6K, 4EBP1 and ULK1, the downstream direct targets that mediate 
the cellular effects of TORC1 signaling are largely unaccounted for. In addition, how the 
specificity of TORC1 signaling is achieved and how multiple signals are integrated is not 
known. Concerning TORC2, the upstream regulators are poorly defined. This knowledge 
seems to be of great significance since mTOR is considered a central node of intracellular 
signaling network and deregulation of its activity strongly contributes to the wide spectrum 
of human diseases. Further studies will give us a better understanding of the whole picture 
of mTORC1/mTORC2 functioning that could be applied to the development of new 
approaches to the treatment of mTOR-associated diseases. 
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